Skip Navigation LinksHome > December 2013 - Volume 61 - Issue 8 > Plasma Adropin Levels Predict Endothelial Dysfunction Like F...
Journal of Investigative Medicine:
doi: 10.231/JIM.0000000000000003
Original Articles

Plasma Adropin Levels Predict Endothelial Dysfunction Like Flow-Mediated Dilatation in Patients With Type 2 Diabetes Mellitus

Topuz, Mustafa MD*; Celik, Ahmet MD; Aslantas, Tutku MD; Demir, Ayse Kevser MD§; Aydin, Suna MD; Aydin, Suleyman MD

Collapse Box

Abstract

Objective

This study investigated the role of plasma adropin levels to show endothelial dysfunction in individuals with type 2 diabetes mellitus and to compare these with flow-mediated dilatation.

Methods

A total of 92 individuals with diagnosed type 2 diabetes mellitus were included and divided into 2 groups according to their brachial flow-mediated dilatation. The endothelial dysfunction group consisted of 46 participants with flow-mediated dilatation change of less than 7%, whereas 46 participants with flow-mediated dilatation change of more than 7% were accepted as the nonendothelial dysfunction group. Venous blood samples were taken from all study participants, and plasma adropin levels were measured using an enzyme-linked immunosorbent assay kit.

Results

The mean flow-mediated dilatation values were 13.2% ± 4.9% in the nonendothelial dysfunction group, and 3.5% ± 3.4% in the endothelial dysfunction group. Mean hemoglobin A1c levels were significantly higher in the endothelial dysfunction group than in the nonendothelial dysfunction group (8.7% ± 1.9% vs 7.9% ± 1.6%, respectively; P < 0.038). Mean plasma adropin levels were 3.04 ± 0.79 ng/mL in the endothelial dysfunction group and 4.67 ± 1.43 ng/mL in the nonendothelial dysfunction group; P < 0.001. Plasma adropin levels showed no correlation with body mass index (r = −0.072, P = 0.497) but were positively correlated with flow-mediated dilatation values (r = 0.537, P < 0.001). In the linear regression analysis, adropin and hemoglobin A1c were independent risk factors for endothelial dysfunction in individuals with type 2 diabetes mellitus.

Conclusion

Adropin is a new marker for use in demonstrating endothelial dysfunction.

Copyright © 2013 by The American Federation for Medical Research

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.